11
Total investments
2
Early stage
0
Mid stage
5
Late stage
16y
Years active
Portfolio
10 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Observer | Lead Investor
Jun 2025
D&D is a clinical-stage global biotech company that focuses on development and commercialization of revolutionary medicines with the potential to change the lives of patients with unmet medical needs. Our success is built on a product pipeline originating from top research centers.
Close collaborations with leading research institutes worldwide provide us with a unique opportunity to accelerate translation of cutting-edge research into revolutionary lifesaving therapeutic products for patients.
Lead Investor
2022
〈テクノロジーのチカラで 持続可能な世界をつくる。〉
私たちは「世の中の全てを「as a Service」へ」をMissionに掲げています。
日本、世界における労働生産性を上げ、1人1人の「人生」における「働く価値」をよりポジティブなものにしたい。
そんな想いを持って一緒に働いてくれるあなたを待っています。
Board Observer
Nov 2021
Conquer Cancer through AI.
Lunit is a public company that develops medical AI software for cancer screening and treatment.
Lunit AI can empower you to enhance diagnostic performance. Our AI for chest x-ray and 2D & 3D mammography has been validated through 100+ publications in peer-reviewed journals such as JAMA Oncology, Lancet Digital Health and Radiology, and is now in use in 3,500+ sites globally.
< Lunit AI Suite for Radiology >
• Lunit INSIGHT CXR, AI Solution for Chest X-ray
• Lunit INSIGHT MMG, AI Solution for Mammography
• Lunit INSIGHT DBT, AI Solution for Digital Breast Tomosynthesis
• Lunit CXR Triage, AI solution for Chest X-ray Triage *emergency department use, available in the US only
*If you are interested in Lunit Oncology, please visit Lunit Oncology’s LinkedIn page.
Board Observer
2020
LianBio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in China and other major Asian markets through partnerships that provide access to innovative therapeutic discoveries.
Board Observer
2020
Developing potentially best-in-class, novel small molecules targeting fundamental biological pathways in cancer
Board Observer
2019
We are a groundbreaking science-based company creating scalable, safer insect control technology that will improve the quality of life for all humans and our world.
Lead Investor (Series I2)
2018
Ola is India’s largest mobility platform and one of the world’s largest ride-hailing companies, serving 250+ cities across India, Australia, New Zealand, and the UK. The Ola app offers mobility solutions by connecting customers to drivers and a wide range of vehicles across bikes, auto-rickshaws, metered taxis, and cabs, enabling convenience and transparency for hundreds of millions of consumers and over 1.5 million driver-partners.
Ola’s core mobility offering in India is supplemented by its electric-vehicle arm, Ola Electric; India’s largest fleet management business, Ola Fleet Technologies and Ola Skilling, that aims to enable millions of livelihood opportunities for Indias youth. With its acquisition of Ridlr, India’s leading public transportation app and investment in Vogo, a dockless scooter sharing solution, Ola is looking to build mobility for the next billion Indians. Ola also extends its consumer offerings like micro-insurance and credit led payments through Ola Financial Services and a range of owned food brands through India’s largest network of kitchens under its Food business.
Ola was founded in 2011 by Bhavish Aggarwal and Ankit Bhati with a mission to build mobility for a billion people. For more details, visit www.olacabs.com/media
Board Observer and Lead Investor
2017
Were transforming the global food system by creating better ways to make meat, dairy and fish without using animals -- delicious, good for people, and good for the planet. Our approach: understand what people love about meat, dairy, and fish, and then explore the plant world for specific ingredients that recreate those experiences. In 2016, we launched the Impossible™ Burger: meat made from plants, for people who love to eat meat.
Founded in 2011 by Pat Brown MD, PhD (Stanford Professor Emeritus) and backed by top-tier VCs and visionaries, we’re looking for the very best scientists, engineers, food developers, and business professionals in the world to join our creative, diverse, multi-talented and mission-driven team. We’re here to secure a sustainable future (and have fun while doing it). Come work with us to change the course of history.
Board Observer
2010
Cheetah Medical is a leader in non-invasive Cardiac Output and Hemodynamic monitoring.
Cheetah’s proprietary CHEETAH NICOM Reliant and Starling SV systems are CE marked and FDA cleared.
Cheetah Medical’s CHEETAH NICOM Reliant and Starling SV systems are now used by leading medical centers around the globe providing clinicians with invaluable clinical information in complicated scenarios. Cheetah Medical is committed to ongoing research and development and close cooperation with clinicians.
CHEETAH NICOM is the only non-invasive hemodynamic and cardiac output monitor whose predicate for FDA clearance was the gold standard Continuous Cardiac Output Swan-Ganz catheter (pulmonary artery catheter).
Cheetah medical was founded in 2000 and focused on development and commercialization of an accurate non-invasive solution for the monitoring of critically ill patients.
Cheetah Medical is a private company based in Newton, Massachusetts, Tel-Aviv, Israel and Portland, Oregon.
Experience · 18 entries
All (18)
Investments (11)
Board (7)
2025
Board Observer | Lead Investor
Jun 2025
D&D is a clinical-stage global biotech company that focuses on development and commercialization of revolutionary medicines with the potential to change the lives of patients with unmet medical needs. Our success is built on a product pipeline originating from top research centers.
Close collaborations with leading research institutes worldwide provide us with a unique opportunity to accelerate translation of cutting-edge research into revolutionary lifesaving therapeutic products for patients.
2023
2022
Lead Investor
2022
〈テクノロジーのチカラで 持続可能な世界をつくる。〉
私たちは「世の中の全てを「as a Service」へ」をMissionに掲げています。
日本、世界における労働生産性を上げ、1人1人の「人生」における「働く価値」をよりポジティブなものにしたい。
そんな想いを持って一緒に働いてくれるあなたを待っています。
2021
Board Observer
Nov 2021
Conquer Cancer through AI.
Lunit is a public company that develops medical AI software for cancer screening and treatment.
Lunit AI can empower you to enhance diagnostic performance. Our AI for chest x-ray and 2D & 3D mammography has been validated through 100+ publications in peer-reviewed journals such as JAMA Oncology, Lancet Digital Health and Radiology, and is now in use in 3,500+ sites globally.
< Lunit AI Suite for Radiology >
• Lunit INSIGHT CXR, AI Solution for Chest X-ray
• Lunit INSIGHT MMG, AI Solution for Mammography
• Lunit INSIGHT DBT, AI Solution for Digital Breast Tomosynthesis
• Lunit CXR Triage, AI solution for Chest X-ray Triage *emergency department use, available in the US only
*If you are interested in Lunit Oncology, please visit Lunit Oncology’s LinkedIn page.
2020
Board Observer
2020
LianBio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in China and other major Asian markets through partnerships that provide access to innovative therapeutic discoveries.
Show all 18 entries ↓
Investment activity
2010–2025 · 11 investments
Recent (last 2 years)Earlier
